Ermeza Patent Expiration

Ermeza is a drug owned by Mylan Pharmaceuticals Inc. It is protected by 1 US drug patent filed in 2022 out of which none have expired yet. Based on its patents and exclusivities, its generic launch date is estimated to be Feb 27, 2035. Details of Ermeza's patents and their expiration are given in the table below.

Drug Patent Number Drug Patent Title Drug Patent Expiry Status
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US9345772 Liquid levothyroxine formulations
Feb, 2035

(10 years from now)


Stay ahead of others in designing the generic launch strategy of these 5 blockbuster drugs expiring in next 5 years.

Get the exclusive patent insights now. Don't be the last to know.

US patents provide insights into the exclusivity only within the United States, but Ermeza is protected by patents in multiple countries. Understanding the full scope of patent protection is crucial in strategizing market entry. By looking at the broader patent landscape, you can identify markets with weaker patent protection which could be ideal generic entry points. The following section offers details on Ermeza's family patents as well as insights into ongoing legal events on those patents.

Ermeza's family patents

Family Patents

Coming Soon

Patent Strength Analyzer

Will this be useful for you?


Thank you for your response 🥳

Generic Launch

Generic Release Date:

Ermeza's generic launch date based on the expiry of its last outstanding patent is estimated to be Feb 27, 2035 (This date is subject to change depending upon the patent filing activities by the drug owner or exclusivity additions to its drug application)

Ermeza Generics:

Levothyroxine Sodium is the generic name for the brand Ermeza. 14 different companies have already filed for the generic of Ermeza, with Mylan having the maximum number of approved applications. Check out the entire list of companies who have already received approval for Ermeza's generic

About Ermeza

Ermeza is a drug owned by Mylan Pharmaceuticals Inc. Ermeza uses Levothyroxine Sodium as an active ingredient. Ermeza was launched by Mylan in 2022.

Market Authorisation Date:

Ermeza was approved by FDA for market use on 29 April, 2022.

Active Ingredient:

Ermeza uses Levothyroxine Sodium as the active ingredient. Check out other Drugs and Companies using Levothyroxine Sodium ingredient


Ermeza is available in solution form for oral use. Given below is detailed information on Dosage -

Strength Dosage Form Availability Application Pathway
150MCG/5ML SOLUTION Prescription ORAL